Webinar: How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization

July 28, 2026

Webinar: How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization


You can have breakthrough technology and still watch it stall. For medical device innovators, the hardest part of commercialization often isn't the science or even FDA clearance: it's getting payers to cover and pay for it. Payer adoption is the most critical, and most misunderstood, determinant of whether your technology reaches patients at scale.


Go behind the payer curtain with former payer medical directors Dr. Julie Kessel and Dr. Dorothea Verbrugge, who spent years making the very kinds of coverage decisions your technology will face, in PRIA’s July 28th webinar, How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization.


Along with PRIA’s veteran market access strategists Kristofer Munroe and Lavanya Subbarayan, get a practical, insider look at what it takes to give your technology a fair review for coverage and adoption, and the moves that separate the technologies that get covered from the ones that don’t.


Our special guests and our own experts walk through how coverage decisions are developed in real-world settings, including how payers identify unmet medical need, evaluate clinical and economic evidence, and assess the value proposition of emerging technologies.


Hear directly from people who have sat on the payer side of the table: how coverage guidelines really get formed, how evidentiary thresholds are shifting, and the specific missteps that can sink otherwise strong technologies. You’ll learn practical tips and tricks for positioning your technology, articulating value, and building an evidence strategy that resonates with both payers and the providers who buy from you.


If you are a medical device innovator who wants to know what payers will require before you commit your next round of regulatory, clinical, or commercial spend, this is an hour that could save you from an expensive misstep.



Panelists:

,


Click the Icon below to share this with your network

From Reimbursement to Resource Allocation: How the Rules for Med Tech Adoption are Being Rewritten
By Jessica Holmes, MJ June 30, 2026
From Reimbursement to Resource Allocation: How the Rules for Med Tech Adoption are Being Rewritten
Stop Guessing What FDA Wants by Sam Murray
By Sam Murray June 4, 2026
Stop Guessing What FDA Wants
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough & Beyond
June 3, 2026
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough and Beyond
You Got Your 510(k). Now What?
By Suzy Engwall May 28, 2026
You Got Your 510(k). Now What?
Right Sizing Your Quality System by Sam Murray
By Sam Murray, Head of Regulatory & Quality May 21, 2026
Right Sizing Your Quality System
Cleared for takeoff: Insights from a Medtech First Officer
By Suzy Engwall May 19, 2026
Five Mistakes MedTech StartUps Make Before Their First VAC Meeting
Using Regulatory as a Strategy and Not a Milestone
By Sam Murray, PRIA May 14, 2026
Using Regulatory as a Strategy and Not a Milestone
Reading the Water: Navigating What Matters in Regulatory and Quality  - Sam Murray, PRIA
By Sam Murray, Head of Regulatory & Quality May 6, 2026
An informative article series from PRIA Healthcare's Head of Regulatory and Quality, Sam Murray
Medical device strategy CMS/FDA RAPID program
April 24, 2026
PRIA examines the impact of the RAPID program, accelerating Medicare access for Breakthrough Devices by aligning FDA approval & CMS coverage, earlier, on innovators.
MedTech Clinical Evidence Strategy
By PRIA Healthcare April 20, 2026
PRIA's experts on reimbursement and regulatory issues weigh in on CMS's proposed NTAP change, and what it may mean for MedTech innovations.
PRIA Healthcare welcomes Sam Murray as Head of Regulatory and Quality Services
March 10, 2026
PRIA Healthcare is thrilled to announce that Sam Murray has joined PRIA as our Head of Regulatory and Quality. Sam brings more than a decade of experience doing exactly that kind of high-stakes, high-impact regulatory work across medical devices, diagnostics, combination products, and software-enabled technologies.
PRIA a strategic and execution partner for reimbursement and market access
By Tonya Dowd, MPH, Executive Vice President, Reimbursement, Health Economics, Market Access and Corporate Development February 23, 2026
MedTech reimbursement and market access, core drivers of valuation, acquisition potential, and long-term viability, should be developed in sync with your regulatory strategy